155 related articles for article (PubMed ID: 30942459)
21. Role of triptolide in cell proliferation, cell cycle arrest, apoptosis and histone methylation in multiple myeloma U266 cells.
Zhao F; Chen Y; Zeng L; Li R; Zeng R; Wen L; Liu Y; Zhang C
Eur J Pharmacol; 2010 Nov; 646(1-3):1-11. PubMed ID: 20547150
[TBL] [Abstract][Full Text] [Related]
22. DNA-PK-mediated phosphorylation of EZH2 regulates the DNA damage-induced apoptosis to maintain T-cell genomic integrity.
Wang Y; Sun H; Wang J; Wang H; Meng L; Xu C; Jin M; Wang B; Zhang Y; Zhang Y; Zhu T
Cell Death Dis; 2016 Jul; 7(7):e2316. PubMed ID: 27468692
[TBL] [Abstract][Full Text] [Related]
23. Fuse-binding protein 1 is a target of the EZH2 inhibitor GSK343, in osteosarcoma cells.
Xiong X; Zhang J; Liang W; Cao W; Qin S; Dai L; Ye D; Liu Z
Int J Oncol; 2016 Aug; 49(2):623-8. PubMed ID: 27278257
[TBL] [Abstract][Full Text] [Related]
24. Yin Yang 1-mediated epigenetic silencing of tumour-suppressive microRNAs activates nuclear factor-κB in hepatocellular carcinoma.
Tsang DP; Wu WK; Kang W; Lee YY; Wu F; Yu Z; Xiong L; Chan AW; Tong JH; Yang W; Li MS; Lau SS; Li X; Lee SD; Yang Y; Lai PB; Yu DY; Xu G; Lo KW; Chan MT; Wang H; Lee TL; Yu J; Wong N; Yip KY; To KF; Cheng AS
J Pathol; 2016 Apr; 238(5):651-64. PubMed ID: 26800240
[TBL] [Abstract][Full Text] [Related]
25. UTX/KDM6A Loss Enhances the Malignant Phenotype of Multiple Myeloma and Sensitizes Cells to EZH2 inhibition.
Ezponda T; Dupéré-Richer D; Will CM; Small EC; Varghese N; Patel T; Nabet B; Popovic R; Oyer J; Bulic M; Zheng Y; Huang X; Shah MY; Maji S; Riva A; Occhionorelli M; Tonon G; Kelleher N; Keats J; Licht JD
Cell Rep; 2017 Oct; 21(3):628-640. PubMed ID: 29045832
[TBL] [Abstract][Full Text] [Related]
26. Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control.
Pawlyn C; Bright MD; Buros AF; Stein CK; Walters Z; Aronson LI; Mirabella F; Jones JR; Kaiser MF; Walker BA; Jackson GH; Clarke PA; Bergsagel PL; Workman P; Chesi M; Morgan GJ; Davies FE
Blood Cancer J; 2017 Mar; 7(3):e549. PubMed ID: 28362441
[TBL] [Abstract][Full Text] [Related]
27. Selective inhibition of EZH2 by ZLD10A blocks H3K27 methylation and kills mutant lymphoma cells proliferation.
Song X; Zhang L; Gao T; Ye T; Zhu Y; Lei Q; Feng Q; He B; Deng H; Yu L
Biomed Pharmacother; 2016 Jul; 81():288-294. PubMed ID: 27261606
[TBL] [Abstract][Full Text] [Related]
28. Quantification of histone H3 Lys27 trimethylation (H3K27me3) by high-throughput microscopy enables cellular large-scale screening for small-molecule EZH2 inhibitors.
Luense S; Denner P; Fernández-Montalván A; Hartung I; Husemann M; Stresemann C; Prechtl S
J Biomol Screen; 2015 Feb; 20(2):190-201. PubMed ID: 25409661
[TBL] [Abstract][Full Text] [Related]
29. [EZH2 is therapeutic target for personalized treatment in multiple myeloma].
Herviou L; Cavalli G; Moreaux J
Bull Cancer; 2018 Sep; 105(9):804-819. PubMed ID: 30041976
[TBL] [Abstract][Full Text] [Related]
30. Study on the Effect of EZH2 Inhibitor Combined with TIGIT Monoclonal Antibody against Multiple Myeloma Cells.
Liu Z; Jia Y; Yang C; Liu H; Shen H; Wang H; Fu R
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37239949
[TBL] [Abstract][Full Text] [Related]
31. Enhancer of zeste homolog 2 depletion induces cellular senescence via histone demethylation along the INK4/ARF locus.
Jie B; Weilong C; Ming C; Fei X; Xinghua L; Junhua C; Guobin W; Kaixiong T; Xiaoming S
Int J Biochem Cell Biol; 2015 Aug; 65():104-12. PubMed ID: 26004298
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of EZH2 via activation of SAPK/JNK and reduction of p65 and DNMT1 as a novel mechanism in inhibition of human lung cancer cells by polyphyllin I.
Li L; Wu J; Zheng F; Tang Q; Wu W; Hann SS
J Exp Clin Cancer Res; 2016 Jul; 35(1):112. PubMed ID: 27421653
[TBL] [Abstract][Full Text] [Related]
33. Design, Synthesis, and Biological Evaluation of a Potent Dual EZH2-BRD4 Inhibitor for the Treatment of Some Solid Tumors.
Huang N; Liao P; Zuo Y; Zhang L; Jiang R
J Med Chem; 2023 Feb; 66(4):2646-2662. PubMed ID: 36774555
[TBL] [Abstract][Full Text] [Related]
34. Dysregulation of EZH2/miR-138 axis contributes to drug resistance in multiple myeloma by downregulating RBPMS.
Rastgoo N; Pourabdollah M; Abdi J; Reece D; Chang H
Leukemia; 2018 Nov; 32(11):2471-2482. PubMed ID: 29743723
[TBL] [Abstract][Full Text] [Related]
35. Diosgenin exhibits tumor suppressive function via down-regulation of EZH2 in pancreatic cancer cells.
Guo W; Chen Y; Gao J; Zhong K; Wei H; Li K; Tang M; Zhao X; Liu X; Nie C; Yuan Z
Cell Cycle; 2019 Aug; 18(15):1745-1758. PubMed ID: 31213123
[TBL] [Abstract][Full Text] [Related]
36. The expression and significance of the enhancer of zeste homolog 2 in lung adenocarcinoma.
Lv Y; Yuan C; Xiao X; Wang X; Ji X; Yu H; Wu Z; Zhang J
Oncol Rep; 2012 Jul; 28(1):147-54. PubMed ID: 22552406
[TBL] [Abstract][Full Text] [Related]
37. Enhancer of Zeste Homolog 2 Inhibition Attenuates Renal Fibrosis by Maintaining Smad7 and Phosphatase and Tensin Homolog Expression.
Zhou X; Zang X; Ponnusamy M; Masucci MV; Tolbert E; Gong R; Zhao TC; Liu N; Bayliss G; Dworkin LD; Zhuang S
J Am Soc Nephrol; 2016 Jul; 27(7):2092-108. PubMed ID: 26701983
[TBL] [Abstract][Full Text] [Related]
38. EZH2 suppresses the nucleotide excision repair in nasopharyngeal carcinoma by silencing XPA gene.
Huang Y; Wang X; Niu X; Wang X; Jiang R; Xu T; Liu Y; Liang L; Ou X; Xing X; Li W; Hu C
Mol Carcinog; 2017 Feb; 56(2):447-463. PubMed ID: 27253463
[TBL] [Abstract][Full Text] [Related]
39. Biological evaluation of tanshindiols as EZH2 histone methyltransferase inhibitors.
Woo J; Kim HY; Byun BJ; Chae CH; Lee JY; Ryu SY; Park WK; Cho H; Choi G
Bioorg Med Chem Lett; 2014 Jun; 24(11):2486-92. PubMed ID: 24767850
[TBL] [Abstract][Full Text] [Related]
40. Phosphorylation-mediated EZH2 inactivation promotes drug resistance in multiple myeloma.
Kikuchi J; Koyama D; Wada T; Izumi T; Hofgaard PO; Bogen B; Furukawa Y
J Clin Invest; 2015 Oct; 125(12):4375-90. PubMed ID: 26517694
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
